Cardiovascular
ICON has extensive experience in conducting cardiovascular clinical research trials across the entire drug development spectrum, ranging from the initial studies in Phase I through post-marketing efforts in Phase IV. ICON also provides specialist imaging expertise and an extensive range of specialised assays to support any cardiovascular indication.
Related Information
Related News
- ICON selected by Genomics England to support the largest genome sequencing project of its kind for cancer and rare diseases »
- ICON Accelerates Site Activation Timelines by up to 25% »
- ICON Acquires PMG Research Inc. »
- ICON Strengthens Global Scientific Council with the Appointments of Professor Brendan Buckley and Dr. Nicholas Alp »
- 269 Cardiovascular studies
- 151,519 Involving over 151,519 patients
- 11,524 Sites worldwide
Our clinical trial experience includes but is not limited to the following cardiovascular indications:
- Acute coronary syndrome (ACS)
- Anticoagulation
- Angina
- Arrhythmias
- Atherosclerosis
- Atrial Fibrillation
- Cardiovascular Prevention
- Cerebrovascular Disease
- Congestive Heart Failure
- Coronary Artery Disease
- Hypertension
- Myocardial Infarction
- Peripheral Artery Disease
- Pulmonary Artery Hypertension
- Stroke
- Thrombosis
Cardiovascular Therapeutic Area Group (TAG)
ICON has a global team of in-house Cardiovascular experts, known as a Therapeutic Area Group (TAG), who are highly-experienced in clinical research and drug development. The group includes representatives from all critical functional areas and oversees trial operations in order to anticipate and proactively address potential roadblocks. In addition to providing support and guidance to the study team, the other main responsibilities of the TAG teams include:
|
|
Investigative Sites
Our global investigator database includes over 2,800 cardiovascular investigative sites across more than 55 countries. As such, we have established solid working relationships with leading cardiovascular sites in all regions of the world, enabling us to provide our sponsors with efficient recruitment strategies tailored to each individual study. We have worked with a wealth of specialty investigators in multiple areas of cardiovascular disease.